Annual Aclasta cuts risk of osetoportic fracture

24 September 2006

Swiss drugmaker Novartis says that data from a Phase III trial of Aclasta (zoledronic acid) demonstrates that the drug reduces the incidence of bone fracture in post-menopausal women with osteoporosis. The results, which are from the HORIZON trial program, were presented to a meeting of the American Society of Bone and Mineral Research in Philadeliphia, USA.

The study found that an annual 5mg dose of the product, known by the proposed trade name Reclast in the USA, brought about a reduction in the risk of new spinal and hip fractures 70% and 40%, respectively, when compared with placebo. In addition, the results showed that the drug's effect was sustained for a three-year period.

Novartis also reported data from a second assessment, which revealed that patients taking oral alendronate could switch directly to treatment with Aclasta and maintain beneficial bone effects for a full 12 months after a single dose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight